Age, years
|
62 [23, 90]
|
58 [23, 75]
|
62 [27, 84]
|
68 [48, 90]
|
Male/female
|
33/22
|
9/8
|
15/9
|
9/5
|
BMI, kg/m2
|
24.8 [15.2, 94.5]
|
24.0 [16.8, 94.5]
|
25.0 [20.4, 49.2]
|
26.0 [19.0, 30.1]
|
CRP d1 (mg/dL)
|
12.0 [0.7, 36.4]
|
9.8 [0.7, 32.5]
|
13.8 [1.1 28.2]
|
12.7 [0.7, 36.4]
|
ΔCRP (d1–d3, mg/dL)
|
3.0 [− 17.1, 18.2]
|
− 0.3 [− 17.1, 17.9]
|
4.5 [− 11.5, 12.8]
|
4.45 [− 6.0, 18.2]
|
IL-6 d1 (pg/mL)
|
93.1 [4, 2469]
|
101 [50.6, 470]
|
90.2 [5.1, 530]
|
108.2 [10.7, 2469]
|
ΔIL-6 (d1–d3, pg/dL)
|
48 [− 727, 2327]
|
50 [− 727, 433]
|
46.5 [− 138, 486]
|
84.7 [− 68.1, 2327]
|
APACHE II d1
|
25 [12, 51]
|
24 [16, 34]
|
25 [12, 37]
|
28.5 [18, 51]
|
ΔAPACHE–II (d1–d3)
|
4 [− 13, 22]
|
8 [− 6, 17]
|
3 [− 7, 22]
|
4 [− 13, 14]
|
SOFA d1
|
10 [3, 19]
|
9 [3, 14]
|
11 [5, 16]
|
11 [3, 19]
|
ΔSOFA (d1–d3)
|
4 [− 8, 9]
|
2 [− 8, 9]
|
2 [− 2, 7]
|
2 [− 4, 6]
|
Body temperature > 38.0 °C d1
|
17 (30.1)
|
4 (23.5)
|
9 (37.5)
|
4 (28.6)
|
Catecholamine therapy d1
|
45 (81.8)
|
12 (70.6)
|
20 (83.3)
|
13 (92.9)
|
Invasive ventilation d1
|
41 (74.5)
|
11 (64.7)
|
18 (75.0)
|
12 (85.7)
|
Bilirubin d1 (mg/dL)
|
0.9 [0.2, 11.9]
|
0.8 [0.2, 10]
|
0.9 [0.2, 4.9]
|
0.9 [0.4, 11.9]
|
ΔBilirubin (d1–d5, mg/dL)
|
0.2 [− 6.1, 8.7]
|
0.2 [− 1.5, 1.1]
|
0.2 [− 0.3, 2.3]
|
0.1 [− 6.1, 8.7]
|
AST d1 (U/L)
|
69.5 [16, 1359]
|
92 [52, 850]
|
64 [16, 1359]
|
61 [25, 693]
|
ΔAST (d1–d5, U/L)
|
25 [− 563, 1223]
|
47 [− 60, 792]
|
8 [− 563, 1223]
|
0 [− 168, 645]
|
ALT d1 (U/L)
|
29 [7, 2018]
|
28 [14, 987]
|
30 [8, 2018]
|
23 [7, 695]
|
ΔALT (d1–d5, U/L)
|
− 3 [− 322, 1662]
|
− 3 [− 40, 741]
|
− 5 [− 322, 1662]
|
1 [− 250, 415]
|
GGT d1 (U/L)
|
38 [11, 850]
|
28 [14, 547]
|
41 [11, 850]
|
97.5 [11, 618]
|
ΔGGT (d1–d5, U/L)
|
− 30 [− 1643, 457]
|
− 30 [− 522, 249]
|
− 29.5 [− 603, 101]
|
− 30.5 [− 1643, 457]
|
Creatinine d1 (mg/dL)
|
0.8 [0.4, 5.3]
|
0.7 [0.5, 1.2]
|
0.8 [0.6, 1.8]
|
1.2 [0.8, 5.3]
|
Δ creatinine (d1–d5, mg/dL)
|
0.05 [–3.4, 2]
|
0.0 [− 0.3, 2]
|
0.1 [–0.5, 0.7]
|
0.0 [–3.4, 0.4]
|
Urea d1 (mg/dL)
|
34 [18,131]
|
30.5 [18, 61]
|
34 [20, 131]
|
71 [29, 113]
|
Δ urea (d1–d5, mg/dL)
|
− 9.5 [− 134, 51]
|
− 9.5 [− 48, 9]
|
− 7 [− 134, 51]
|
− 23 [− 76, 27]
|
CLCR d1 (mL/min)
|
79 [4, 200]
|
146.5 [59, 200]
|
76 [13, 170]
|
42 [4, 80]
|
Δ CLCR (d1–d5, mL/min)
|
− 17 [− 139, 78]
|
5.5 [− 139, 78]
|
− 24.5 [− 116, 70]
|
− 10 [− 41, 3]
|
RRT
|
9 (16.4)
|
1 (5.9)
|
3 (12.5)
|
5 (35.7)
|
ECMO d1
|
2 (3.6)
|
0 (0.0)
|
1 (4.2)
|
1 (7.1)
|
In-hospital mortality
|
13 (23.6)
|
3 (17.6)
|
2 (8.3)
|
8 (57.1)
|
Trough-level meropenem (mg/L)
|
5.0 [0.25, 65.3]
|
1.85 [0.25, 20.4]
|
5.4 [2.17, 27.4]
|
18.3 [8.48, 65.3]
|
Trough-level piperacillin (mg/L)
|
40.1 [0.5, 400]
|
8.09 [0.5, 27.2]
|
25 [7.2, 156]
|
89.2 [46, 400]
|